Encorafenib plus binimetinib in patients with BRAF^{v600}-mutant non-small cell lung cancer: Phase II PHAROS study design

Authors: Gregory J Riely, Myung-Ju Ahn, Enriqueta Felip, Suresh S Ramalingam, Egbert F Smit, Anne S Tsao, Ann Alcasid, Tiziana Usari, Paul S Wissel, Keith D Wilner & Bruce E Johnson

Article URL: https://www.futuremedicine.com/doi/10.2217/FON-2021-1250

Trial registration numbers: NCT03915951 (ClinicalTrials.gov); 2019-000417-37 (EudraCT)

Objective and rationale


Primary objective

Evaluate the antitumor activity of encorafenib plus binimetinib in treatment-naïve and previously treated patients with BRAF^{V600}-mutant NSCLC as measured by ORR and determined by IRR

Rationale

?)

BRAF/MEK combination therapy is approved in BRAF^{V600}-mutant NSCLC, and encorafenib plus binimetinib has shown a manageable safety profile and antitumor activity in patients with metastatic melanoma



Glossary: BID: Twice daily; CNS: Central nervous system; DCR: Disease control rate; DOR: Duration of response; ECOG PS: Eastern Cooperative Oncology Group performance status; ILD: Interstitial lung disease; IRR: Independent radiology review; NGS: Next-generation sequencing; NSCLC: Non-small cell lung cancer; ORR: Objective response rate; OS: Overall survial; PCR: Polymerase chain reaction; PFS: Progression-free survival; QD: Once daily; RECIST: Response Evaluation Criteria in Solid Tumors; TTR: Time to tumor response

www.futuremedicine.com

Funding: This study was sponsored by Array Biopharma, which was acquired by Pfizer in July 2019. Review and formatting assistance for this infographic was provided by Stephanie Springer, of CMC Affinity, McCann Health Medical Communications, and funded by Pfizer. Pfizer funded the development of this infographic and was given the opportunity to review the content for medical and scientific accuracy.

©2021 Gregory J. Riely